Hepaglide vs Ozempic: Comparison Guide
A practical, evidence-aware guide to hepaglide vs ozempic with the correct semaglutide brand context for India.
Hepaglide vs Ozempic: Comparison Guide
If you are comparing Hepaglide and Ozempic, the key point is that both are being discussed as semaglutide brands. Hepaglide is not pemvidutide and should not be framed as a dual GLP-1/glucagon research drug.
This guide compares the products using the correct India-market context so you can discuss them more clearly with your doctor. Consult your healthcare provider before starting any medication.
What is Ozempic?
Ozempic is Novo Nordisk's brand for semaglutide, a GLP-1 receptor agonist. It is commonly used in adults with type 2 diabetes and is also widely discussed because semaglutide can reduce appetite and support weight change in some patients.
Ozempic is given as a once-weekly injection.
What is Hepaglide?
Hepaglide is an Alkem semaglutide injection brand in India. Alkem's launch materials list Semasize, Obesema, and Hepaglide as its semaglutide brands and describe DCGI approval for manufacturing and marketing in India.
That means Hepaglide belongs in a semaglutide brand comparison, not in an investigational pemvidutide discussion.
What they have in common
Hepaglide and Ozempic share the same active ingredient: semaglutide.
That means both are discussed in relation to:
- improved glucose control in type 2 diabetes
- slower gastric emptying
- reduced appetite in many users
- weekly injection-based treatment plans
Key differences: Hepaglide vs Ozempic
1. Manufacturer
- Ozempic is made by Novo Nordisk.
- Hepaglide is associated with Alkem in India.
2. India-market positioning
Ozempic is the originator semaglutide brand with global recognition. Hepaglide is part of the newer India-market rollout of semaglutide from a domestic manufacturer.
3. Device and access context
Alkem described both disposable and reusable pen options across its semaglutide launch. Ozempic has its own established pen system. Device workflow and refill experience may therefore differ.
4. Evidence base
Most landmark semaglutide trial data are tied to the broader originator evidence base. Clinicians still use that semaglutide evidence when discussing Hepaglide while also checking local product details and approval context.
Side effects and safety
Because both are semaglutide-based, the expected side-effect pattern is broadly similar. Common effects may include:
- nausea
- vomiting
- diarrhoea
- constipation
- abdominal discomfort
- lower appetite
These effects are often more noticeable when starting treatment or after dose increases.
Bottom line
Hepaglide and Ozempic are both semaglutide injection brands. The main differences are brand, manufacturer, device, and local market context—Alkem's Hepaglide in India versus Novo Nordisk's Ozempic—not a semaglutide-versus-pemvidutide comparison.
A clinician can help you compare those practical differences safely. Consult your healthcare provider before starting any medication.
Sources
- https://admin.alkemlabs.com/uploads/Press_Release_Alkem_Semaglutide_Day_1_launch_final_fc1e90e3be.pdf
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
- https://cdsco.gov.in/opencms/opencms/en/Home/
- https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- https://medlineplus.gov/druginfo/meds/a618008.html
Written by
Dietician / Nutritionist
Health Content Writer
Neha Kumari is a Dietician / Nutritionist professional who contributes evidence-informed health and wellness content for WeightEasy.
View profile →Reviewed by
Immunobiologist
Senior Medical Reviewer
Dr kshama jain is a Immunobiologist professional who reviews WeightEasy health content for medical and editorial accuracy.
View profile →